Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study
Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer: A Single-Institution Cohort Study
复制标题
DOI：
10.1016/j.ijrobp.2014.10.046
复制
发表时间：
2015-03-01
影响因子：
7
通讯作者：
Ricardi, Umberto
中科院分区：
文献类型：
--
作者：
Filippi, Andrea Riccardo;Badellino, Serena;Ricardi, Umberto
目的：为了评估立体定向消融放射治疗（SABR）的疗效及其作为手术治疗结直肠癌肺转移的替代方法的潜在作用，方法和材料：从2004年到2014年，纳入了40例连续患者，他们在肺部进展时接受了SABR作为第一次局部治疗。主要研究终点是总生存期。次要终点是无进展生存率和safety.Results：26例患者（65%）治疗了单个结节，10例患者（25%）治疗了2个结节，3例患者（7.5%）治疗了3个结节，1例患者（2.5%）治疗了4个结节，共59个病灶。递送的生物有效剂量中位数为96戈伊，每天1至8次。中位随访时间为20个月（范围：3-72个月）。1年、2年和5年的总生存率分别为84%、73%和39%，14例患者（35%）死亡。中位总生存期为46个月。25例患者（62.5%）发生进展，中位间隔为8个月; 3例患者（7.5%）在SABR中心观察到失败。无进展生存率分别为49%和27%，在1年和2 years，respectively.Discussion：这一回顾性探索性分析的结果表明，安全性和有效性的SABR在结直肠癌肺寡转移患者的影响，并敦促列入SABR在前瞻性临床试验。(C)2015 Elsevier Inc.
Purpose: To estimate stereotactic ablative radiation therapy (SABR) efficacy and its potential role as an alternative to surgery for the treatment of lung metastases from colorectal cancer.Methods and Materials: Forty consecutive patients who received SABR as first local therapy at the time of lung progression were included, from 2004 to 2014. The primary study endpoint was overall survival. Secondary endpoints were progression-free survival and safety.Results: A single nodule was treated in 26 patients (65%), 2 nodules in 10 patients (25%), 3 in 3 patients (7.5%), and 4 in 1 patient (2.5%), for a total of 59 lesions. The median delivered biological effective dose was 96 Gy, in 1 to 8 daily fractions. Median follow-up time was 20 months (range, 3-72 months). Overall survival rates at 1, 2, and 5 years were, respectively, 84%, 73%, and 39%, with 14 patients (35%) dead. Median overall survival was 46 months. Progression occurred in 25 patients (62.5%), at a median interval of 8 months; failure at SABR site was observed in 3 patients (7.5%). Progression-free survival rates were 49% and 27% at 1 and 2 years, respectively.Discussion: The results of this retrospective exploratory analysis suggest safety and efficacy of SABR in patients affected with colorectal cancer lung oligometastases and urge inclusion of SABR in prospective clinical trials. (C) 2015 Elsevier Inc.